[ 18F]FLT-PET imaging does not always "Light up" proliferating tumor cells

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1303-1312

  Zhang, Cathy C ^a   Yan, Zhengming ^a   Li, Wenlin ^a   Kuszpit, Kyle ^a   Painter, Cory L ^a   Zhang, Qin ^a   Lappin, Patrick B ^a   Nichols, Tim ^a   Lira, Maruja E ^a   Affolter, Timothy ^a   Fahey, Neeta R ^a   Cullinane, Carleen ^b   Spilker, Mary ^a   Zasadny, Kenneth ^a   O'Brien, Peter ^a   Buckman, Dana ^a   Wong, Anthony ^a   Christensen, James G ^a  

^a PFIZER INC   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUORO 3' DEOXYTHYMIDINE F 18; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; KI 67 ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG MONITORING; DRUG UPTAKE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; THYMIDINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863230632     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1433     Document Type: Article

References (30)

1. 18F]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
2. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-72.
3. Paproski RJ, Ng AML, Yao SYM, Graham K, Young JD, Cass CE. The role of human nucleoside transporters in uptake of 3′-deoxy-3′- fluorothymidine. Mol Pharmacol 2008;74:1372-80.
4. Paproski RJ, Wuest M, Jans H-S, Graham K, Gati WP, McQuarrie S, et al. Biodistribution and uptake of 3′-deoxy-3′-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med 2010;51:1447-55.
5. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7. (Pubitemid 34988769)
6. Cole P, Smith A, Kamen B. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol 2002;50:111-6. (Pubitemid 34969505)
7. Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M, Nair J, et al. Imaging colon cancer response following treatment with AZD1152: A preclinical analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]fluorothymidine imaging. Clinical Cancer Res 2011;17: 1099-110.
8. Mankoff DA, Eary JF. Proliferation imaging to measure early cancer response to targeted therapy. Clin Cancer Res 2008;14:7159-60.
9. Weber WA. Monitoring tumor response to therapy with 18F-FLT PET. J Nucl Med 2010;51:841-4.
10. De Saint-Hubert M, Brepoels L, Mottaghy FM. Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT? J Nucl Med 2010;51:1499-500.
11. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, et al. 3′-Deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007;67:11463-9. (Pubitemid 350248575)
12. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, et al. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[18F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET). PLoS One 2008;3:e3908.
13. Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 2010;51:1559-64.
14. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, et al. PF-03732010: A fully human monoclonal antibody against P-Cadherin with antitumor and antimetastatic activity. Clin Cancer Res 2010;16: 5177-88.
15. Sohn H-J, Yang Y-J, Ryu J-S, Oh SJ, Im KC, Moon DH, et al. [18F]Fluorothymidine positron emission tomography beforeand 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
16. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
17. Leonard JP, LaCasce A, Smith MR, Noy A, Yap JT, Van den Abbeele AD, et al. Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma. Blood 2008;112:264.
18. Li W, Araya M, Elliott M, Kang X, Gerk PM, Halquist MS, et al. Monitoring cellular accumulation of 3′-deoxy-3′-fluorothymidine (FLT) and its monophosphate metabolite (FLT-MP) by LC-MS/MS as a measure of cell proliferation in vitro. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2963-70.
19. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol 2004;31:829-37. (Pubitemid 39297680)
20. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007;67:3970-5. (Pubitemid 46762187)
21. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res 2009;15:4630-40.
22. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-Deoxy-3′-[18F] fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65: 4202-10. (Pubitemid 40775658)
23. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. 18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 2009;50:1102-9.
24. Taylor A, Hewitt EG, Jones OW. Tumor-associated thymidine kinase in the sera of rats with transplanted hepatomas. Cancer Res 1976;36: 2070-2.
25. Rehn S, Gronowitz JS, K€allander C, Sundstr€om C, Glimelius B. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. Br J Cancer 1995 71:1099-105.
26. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8. (Pubitemid 36793068)
27. Li KM, Clarke SJ, Rivory LP. Quantitation of plasma thymidine by high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Anal Chim Acta 2003;486: 51-61. (Pubitemid 36694326)
28. Turcotte E, Wiens L, Grierson J, Peterson L, Wener M, Vesselle H. Toxicology evaluation of radiotracer doses of 3′-deoxy-3′-[18F] fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 2007;7:1-9
29. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994;30:391-8. (Pubitemid 24309742)
30. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med 2007;37:429-39. (Pubitemid 47498262)